AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Dr. Amy Wu, Founder and CEO, will present an overview of Antelope’s platform and development pipeline on Wednesday, June 18, 2025, at 10:30 AM ET in Room 153B at the Boston Convention & Exhibition Center.
The presentation will introduce Antelope’s dual-modality platform combining radioligand and fluorescent imaging for use in real-time cancer detection, surgical guidance, and biopsy targeting. The company’s lead asset, AS1986NS, is FDA IND-cleared and entering Phase 1/2 clinical trials in prostate cancer. Built on a flexible small molecule scaffold, AS1986NS is FDA IND-cleared for fluorescent surgical use, with future potential for PET imaging and radiotherapeutic applications currently under development.
“We look forward to engaging with potential partners and investors at BIO,” said Dr. Wu. “Our goal is to bring greater precision to cancer surgery through a unified, scalable platform.”
Antelope Surgical Solutions will participate in BIO’s one-on-one partnering system, and welcomes meetings with potential collaborators.
Antelope is open to motivated clinical collaborators for investigator-initiated pilot studies, as well as high-volume surgical centers interested in participating in its planned Phase 3 trial. Interested investigators or institutions are encouraged to reach out directly.
For more information or to request a meeting, please visit www.antelopesurgical.com or contact [email protected].
Dr. Wu will also have a presence at the Society of Robotic Surgery 2025 Annual Meeting in Strasbourg, France this July. More details to follow.
About Antelope Surgical Solutions
Antelope Surgical Solutions, Inc. is a New York-based biotechnology company developing a dual-modality imaging platform combining radioligand and fluorescent technologies. The company leverages AI-driven drug manufacturing and a proprietary imaging system to enhance surgical decision-making and oncologic outcomes.
Antelope Surgical PR
Antelope Surgical Solutions, Inc.
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
